University of Wisconsin-Madison Professor Sterling Johnson leads one of the world’s largest and longest-running studies of people at risk for Alzheimer’s disease. His team aims to diagnose the disease years before people even develop symptoms and identify ways to slow its progression. He finds his work meaningful and rewarding.
But over the past seven weeks, as President Donald Trump’s administration proposes deep cuts to biomedical research, Johnson has encountered a new feeling. Something he’s never felt since he started studying studying Alzheimer’s in 1997.